BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boof ML, Dingemanse J, Lederer K, Fietze I, Ufer M. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep 2021;44:zsaa275. [PMID: 33305817 DOI: 10.1093/sleep/zsaa275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Markham A. Daridorexant: First Approval. Drugs 2022. [PMID: 35298826 DOI: 10.1007/s40265-022-01699-y] [Reference Citation Analysis]
2 Rosenberg R, Citrome L, Drake CL. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. Neuropsychiatr Dis Treat 2021;17:2549-66. [PMID: 34393484 DOI: 10.2147/NDT.S297504] [Reference Citation Analysis]
3 Ufer M, Kelsh D, Schoedel KA, Dingemanse J. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep 2021:zsab224. [PMID: 34480579 DOI: 10.1093/sleep/zsab224] [Reference Citation Analysis]